Key Takeways U.S.-listed shares of Novo Nordisk plunged 7% in intraday trading Thursday after rival Eli Lilly reported ...

BMO Capital Markets downgraded Novo Nordisk (NYSE:NVO) to “Market Perform” from “Outperform” and cut its price target to $64, saying the Danish drugmaker’s early lead in the obesity drug market is ...

The tortoise (Eli Lilly) has caught the hare (Novo Nordisk), according to a report from BMO Capital Markets, which cites the superior commercial and clinical portfolios of the Indianapolis company ...

Lilly's weight-loss drug trial shows promising results, propelling stock up 14.36%. Goldman Sachs predicts potential $23.5B in sales by 2035.

Eli Lilly’s shares shot up 11% pre-market on Thursday after orforglipron became the first small-molecule GLP-1 drug to ace a ...

Eli Lilly (LLY) announced on Thursday that its weight loss pill has succeeded Phase 3 trials on Type 2 diabetes patients, ...

BMO Capital downgraded Novo Nordisk (NVO) to Market Perform from Outperform with a price target of $64, down from $105. The company’s obesity ...

After massive gains in the past five years on the heels of the weight loss blockbuster Zepbound, Eli Lilly & Co (LLY) stock ...

Eli Lilly’s experimental obesity pill, orforglipron, met its main goals in a closely watched late-stage trial, boosting the company’s standing in the fast-growing market for weight loss and diabetes ...

BigHat Biosciences, a Californian biotech with a machine learning (ML)-guided antibody discovery and development platform, ...

Orforglipron is the first oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist, taken without food and water ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...